You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 6, 2024

Claims for Patent: 10,184,121


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,184,121
Title:Methods for removing viral contaminants from pancreatic extracts
Abstract: Methods for screening pancrelipase for RNA virus contamination comprise removing free viral RNA from the pancrelipase, denaturing any viruses in the pancrelipase to release encapsidated RNA into the pancrelipase milieu, and detecting this released RNA. Removal of free viral RNA may comprise treating pancrelipase with RNase and DNase or precipitating the protein fraction of pancrelipase with a salt that precipitates the protein fraction while leaving nucleic acids such as RNA in solution. Pancrelipase substantially devoid of free nucleic acid is also provided.
Inventor(s): Ortenzi; Giovanni (Monza, IT), Ghidorsi; Luigi (Milan, IT)
Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (Dublin, IE)
Application Number:14/744,447
Patent Claims:1. A method for detecting Hepatitis E virus contamination in a sample comprising pancrelipase, the method comprising (a) treating the sample with a ribonuclease to catalyze degradation of substantially all free RNA in the sample comprising pancrelipase, (b) treating the sample with a ribonuclease inhibitor, (c) treating the sample with an agent to denature capsid of Hepatitis E virus, and (d) amplifying with PCR and detecting encapsidated Hepatitis E virus RNA, wherein the method reduces false positive results of Hepatitis E viral contamination in the sample.

2. The method of claim 1, optionally comprising extracting the encapsidated Hepatitis E virus RNA and amplifying the extracted Hepatitis E virus RNA.

3. The method of claim 1, further comprising treating the pancrelipase with a protease inhibitor.

4. The method of claim 1, wherein the ribonuclease is ribonuclease A.

5. The method of claim 1, wherein the sample of step a) further comprises free RNA and encapsidated Hepatitis E virus.

6. The method of claim 1, wherein the ribonuclease inhibitor comprises 1,4-dithiothreitol (DTT).

7. The method of claim 1, wherein b) further comprises heating pancrelipase and removing a cellular debris via centrifugation or molecular filters.

Details for Patent 10,184,121

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. COTAZYM pancrelipase Capsule, Delayed Release 020580 12/09/1996 ⤷  Try a Trial 2034-06-19
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 04/30/2009 ⤷  Try a Trial 2034-06-19
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 06/10/2011 ⤷  Try a Trial 2034-06-19
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 03/14/2013 ⤷  Try a Trial 2034-06-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.